阿托伐他汀在慢性心力衰竭治疗中对QTd及NT-proBNP影响的临床观察
|
摘要
目的：本课题通过观察阿托伐他汀在在心衰药物基础治疗上对慢性心力衰竭患者QT离散度(QTd)及N末端脑钠肽前体(NT-proBNP)的影响,并探讨其作用机制。
方法：参考全国高等学校教材《内科学》第7版慢性心力衰竭诊断标准,采用随机数字表法将70例患者随机分为两组,治疗组35例,对照组35例,两组患者在入组时一般性资料方面(年龄、性别、病程、病情)均无显著性差异。对照组给予慢性心衰药物基础治疗,治疗组在慢性心衰药物基础治疗上加服阿托伐他汀,疗程为12周。观察治疗前后慢性心衰患者QTd及NT-proBNP的变化。
结果：(1)两组治疗前后QTd及QTcd明显缩小,治疗组QTd及QTcd缩小优于对照组(P<0.01)。(2)两组治疗后,治疗组血浆NT-proBNP均明显下降(P<0.01),与对照组治疗后比较差异也有统计学意义(P<0.05)。
结论：通过本次临床观察,结果显示阿托伐他汀联合慢性心衰药物基础治疗可缩短慢性心力衰竭患者的QT离散度并降低NT-proBNP.
Objective:1:To study the effects of atorvastatin on QTd (qt dispersion) and NT-proBNP in Patients with chronic heart failure, and investigate the possible mechanisms.
Methods:Refer to the Diagnostic criteria of chronic heart failure of The national higher school teaching materials internal medicine,The seventh edition.the Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult,70Patients with chronic heart failure were randomly divided into two groups,35patients were treated with basic Western medicine as control group;35patients were treated with combination therapy of atorvastatin with Western medicine as treatment group.QTd and NT-proBNP levels were measured before and after12week treatmeant.
Results:(1)in two groups,QTd and QTcd levels were both significantly reduced after treatment, especially in treatment group.(2)After treatment, NT-proBNP in blood plasma was decreasing significantly in treatment group(P<0.01), Compared with control group,the decreasing was significantly(P<0.05).
Conclusion:Compared with control group, combination therapy of atorvastatin with basic Western medicine has the obvious curative effect for Patients with chronic heart failure.
方法：参考全国高等学校教材《内科学》第7版慢性心力衰竭诊断标准,采用随机数字表法将70例患者随机分为两组,治疗组35例,对照组35例,两组患者在入组时一般性资料方面(年龄、性别、病程、病情)均无显著性差异。对照组给予慢性心衰药物基础治疗,治疗组在慢性心衰药物基础治疗上加服阿托伐他汀,疗程为12周。观察治疗前后慢性心衰患者QTd及NT-proBNP的变化。
结果：(1)两组治疗前后QTd及QTcd明显缩小,治疗组QTd及QTcd缩小优于对照组(P<0.01)。(2)两组治疗后,治疗组血浆NT-proBNP均明显下降(P<0.01),与对照组治疗后比较差异也有统计学意义(P<0.05)。
结论：通过本次临床观察,结果显示阿托伐他汀联合慢性心衰药物基础治疗可缩短慢性心力衰竭患者的QT离散度并降低NT-proBNP.
Objective:1:To study the effects of atorvastatin on QTd (qt dispersion) and NT-proBNP in Patients with chronic heart failure, and investigate the possible mechanisms.
Methods:Refer to the Diagnostic criteria of chronic heart failure of The national higher school teaching materials internal medicine,The seventh edition.the Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult,70Patients with chronic heart failure were randomly divided into two groups,35patients were treated with basic Western medicine as control group;35patients were treated with combination therapy of atorvastatin with Western medicine as treatment group.QTd and NT-proBNP levels were measured before and after12week treatmeant.
Results:(1)in two groups,QTd and QTcd levels were both significantly reduced after treatment, especially in treatment group.(2)After treatment, NT-proBNP in blood plasma was decreasing significantly in treatment group(P<0.01), Compared with control group,the decreasing was significantly(P<0.05).
Conclusion:Compared with control group, combination therapy of atorvastatin with basic Western medicine has the obvious curative effect for Patients with chronic heart failure.
引文
[1].Kannel WB. Vital epidemiology clues in heart failure.J Clin Epidemiol,2000,53:229-235
[2].Cleland JGF.The heart failure epidemic:exactly how big is it.[J].Eur heart J,2001,22(8):623-626
[3].中华医学会心血管病学分会,中华心血管病杂志编辑部委员会.慢性收缩性心力衰竭治疗建议.[J].中华心血管病杂志,2002,30(6)：7
[4].杨光敏,唐国华,曹林生.心力衰竭发病机制研究进展[J].咸宁学院学报(医学版),2004,18(1)：11
[5]张子彬,Tsung O Cheng充血性心力衰竭(第2版).北京：科学技术文献出版社,1997,49-80.
[6].中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1)：723
[7]夏思良,周建松,嵇平等.血浆脑钠肽前体N-末端水平在慢性收缩性心力衰竭患者中的诊断价值[J].临床内科杂志,2009,26(7)：19.
[8].陆再英.钟南山.内科学[M].第七版,北京,人民卫生出版社,2008,1：174-175
[9]李延辉,那开宪.慢性心力衰竭的历史、现状和未来[J].中华临床杂志,2003,3(4)：53-59.据资料显示心衰患者占心血管病住院患者的20%,病死率却占40%以上[]。
[10]李玉珍,张晓华.慢性心力衰竭治疗的新理念[J].中国城乡企业卫生,2008,22(2)：37-38.
[11]杨红斌.慢性充血性心力衰竭药物治疗的研究进展[J].中国社区医师,2013,15(5)：10.
[12]Chamber DE, etal. MedCellCardioi,1985,17:145.
[13]高林荣.卡托普利联合芪苈强心胶囊治疗慢性肺心病难治性心衰疗效观察[J].中国社区医师,2013,15(5)：205.
[14]田蕊,李玲,苏真珍.β-受体阻滞剂与ACEI在心衰中的应用比较[J].中国民族民间医药,2009,17(16)：67.
[15]镇辉,柴祖德.常规抗心衰药加血管紧张素转换酶抑制剂(ACEI)治疗心力衰竭的疗效观察[J].中国血液流变学杂志,2005,15(4)：616.
[16]史爱民.抗心衰药物β1受体阻滞剂治疗心衰的疗效观察[J].山东生物医学工程,2001,20(3)：65.
[17]陆健.β1-受体阻滞剂治疗COPD并慢性心功能不全的临床观察[J].吉林医学,2011,32(21)：4316-4317.
[18]杜作义,聂如琼,王景峰.倍他乐克对慢性充血性心力衰竭患者心电生理特性的影响[J].吉林医学,广东医学,2001,22(8)：753-754.
[19]施仲伟.β受体治疗对慢性心力衰竭患者临床终点事件的影响[J].中华心血管病杂志,2001,29：504-505.
[20]韩昆峰.阿替洛尔治疗慢性充血性心力衰竭的疗效观察[J].实用心脑肺血管病杂志,2008,16(2)：120-121.
[21]李振魁,祝善俊,黄岚,等.美托洛尔长期治疗对慢性心力衰竭患者心肌重构和炎性细胞因子的影响[J].心脏杂志,2005,17(6)：517-518.
[22]杨丕俊,牛存龙,王书琨,等.美托洛尔治疗慢型克山病的效果观察[J].心脏杂志,2000,19(4)：298-299.
[23]黄登鹏,杨鸣,王少军,等.美托洛尔在治疗慢性肺心病心力衰竭中的应用[J].临床荟萃,2005,20(5)：251-252.
[24]席瑞霞,舒茂琴,张平.比索洛尔对慢性心力衰竭合并心房颤动患者的疗效分析席[J].重庆医学,2005,34(3)：387-388.
[25]梁晓坤.醛固酮受体拮抗剂临床应用研究进展[J].中国伤残医学,2012,20(7)：138-139.
[26]新春,李延辉.慢性心力衰竭治疗中醛固酮拮抗剂的应用[J].中国实用内科杂志,2005,25(7)：588-590.
[27]芦建华,那开宪.选择性醛固酮受体拮抗药依普利酮及其临床应用进展[J].首都医药,2005,12(150)：31-33.
[28]廖春分,丁洪成,廖勇敢.醛固酮受体拮抗剂对足细胞保护机制研究进展[J].实用医学杂志,2012,28(17)：2977-2978.
[29]Zhu C, Huang S, Yuan Y, et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage:A therapeutic target of PPARγ [J]. Am J Pathol,2011,178 (5):2020—2031.
[30]Agostoni P, Magini A, Andreini D, et al. Spironol actone improves lung diffusion in chronic heart failure. Eur H eart J,2005,26:159-164.
[31]杨新春,李延辉主编.现代心血管药物与临床.北京：人民军医出版社,2004.155-160.
[32]王辉华.阿托伐他汀钙对冠心病心力衰竭患者心功能的影响[J].中国医药指南,2012,10(35)：425-426.
[33]朱爱东,何云,张融,等.阿托伐他汀改善冠心病心力衰竭患者心功能的作用[J].重庆医学,2008,37(16)：1804-1805.
[34]Aseer E,Bertolami MC,Venturinelli ML,et al.Atorvaatatin reduces Proinflammatory markeB in hypercholesterolemic patients[J].Atherosclerosis,2004,177(1):161-166.
[35]袁晓利,王成全,高志刚.探讨阿托伐他汀钙在慢性心力衰竭治疗中的作用[J].中国伤残医学,2012,20(11)：91-92.
[36]刘冰.辛伐他汀对心衰大鼠高迁移率族蛋白1水平的影响[J].河北医学,2013,19(1)：53-56.
[37]武智晓,黎明江.阿托伐他汀对心衰患者LVEF影响Meta分析[J].海南医学,2012,23(1)：132-134.
[38]柯天秀,江芸,姜锋.阿托伐他汀对慢性充血性心力衰竭患者B型脑钠肽(BNP)的影响及疗效观察[J].海峡药学,2011,23(12)：116-117.
[39]白桂芝,樊蔚,袁江永,等.阿伐他汀对慢性心力衰竭患者LVEDD及血浆CRP和LDL-C的影响[J].贵阳医学院学报,2011,36(5)：519-520.
[40]邹操,陆文林,宋建平,等.辛伐他汀对心力衰竭家兔左室收缩功能及交感活性的影响[J].临床心血管病杂志,2011,27(9)：705-708.
[41]尚立中,林晓云,马绍椿,等.阿托伐他汀对扩张型心肌病患者心功能及心率变异性的影响.临床心血管病杂志,2004,20(3)：133-135.
[42]周翠珍,殷仁富,任雨笙,等.左旋卡尼汀对心力衰竭患者血清游离脂肪酸浓度的影响.心脏杂志,2004,16(3)：226-227.
[43]Charlap S, Lichstein E, William H, et al.Adrenergicblocking drug in the treatment of Congestive heart failure. Med Cli North Atn,2001,73(27):373.
[44]赵楚敏,王希柱,宋月霞.6分钟步行试验对氟伐他汀治疗慢性心衰的疗效评估[J].中国现代医药杂志,2009,11(12)：104-105.
[45]刘必卫.阿伐他汀治疗慢性心力衰竭39例临床观察[J].中国社区医师.医学专业,2011,13(35)：48
[46]贾志新,孟皓波,迎梅,等.阿司匹林、辛伐他汀和金纳多联合治疗高血压病的疗效分析[J].吉林大学学报(医学版),2011,37(5)：804.
[47]魏辉,李慧,陈礼学.阿托伐他汀对不伴有高胆固醇血症的慢性心衰患者的血管内皮功能的影响[J].心血管康复医学杂志,2010,19(2)：189-192.
[48]Cannon CP, Braunwald E, McCabe CH,etal.Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J]. N Engl J Med,2004,350(15):1495-1504.
[49]黄志军.阿托伐他汀对充血性心力衰竭患者炎症因子的影响[J].山东医药,2008,48(38)：76-77.
[50]Yam ada T, Node K, M ine T, et a.l Long-term effect of atorvastat in on neurohum oral activation and cardiac function in patients with chronic heart failure:a prospective randomized controlled study[J].Am H eart J,2007,153(6):1-8.
[51]赵献明,许春平,曾波,等.阿托伐他汀对充血性心衰患者肾功能的影响[J].中外医疗,2010,30：28-29.
[52]李文霞.阿托伐他汀对冠心病伴高脂血症患者血脂的影响[J].河北医药,2011,33(12)：1825-1826.
[53]袁伟,张尚杰.高胆固醇血症患者血管内皮功能变化及阿托伐他汀调脂治疗对其的影响[J].中西医结合心脑血管病杂志,2010,8：1182-1183.
[54]Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure[J]. JAMA,2006,296(17):2105-2111.
[55]余信强.阿托伐他汀对冠心病慢性心力衰竭患者的心功能和预后的影响[J].江汉大学学报(自然科学版),2009,37(3)：76-78
[56]RAINER U, PLIQUENT M D, KURTIS G, et al. Simvastatin normalizers autonomic neural control in experimental heart failure[J]. Circulation,2003,107(8):2493-2498.
[57]Pliquett RU, Cornish KG, Peuler JD, et al. Simvastatin normalizes autonomic neural control in experimental heart failure[J].Circulation,2003,107(19):2493-2498.
[58]陈晓,刘松.阿托伐他汀对急性心肌梗死合并心衰患者行PCI后血清H s-CRP和Copeptin的影响[J].山东医药,2010,50(5)：49-50.
[59]Kelly D, Squire IB, Khan SQ, et al. C-terminal provaso-press in(copeptin) is associated with left ventricu lardys-function, remodeling, and clin ical heart failu rein survivors of myocardial infarction[J]. J Card Fail,2008,14(9):739-745.
[60]孙俐俐,段丽敏,唐玉龙.阿托伐他汀对急性心肌梗死患者心功能影响研究[J].中国现代医生,2011,49(11)：27-28.
[61]UdeH JA, Ray JG. Primary and seconaary prevention of heart failure with stafins[J]. Expert Rev Cardiovasc Ther,2006,4 (6):917-926.
[62]欧荣华,文书银,邓小键.阿托伐他汀对扩张型心肌病心力衰竭的影响研究[J].医学信息,2011,8：3905-3907.
[63]邱宇安,陈火国,黄绍烈,等.阿托伐他汀对老年慢性心力衰竭患者心功能及高敏C反应蛋白水平的影响[J].临床荟萃,2010,25(17)：1490-1492.
[64]Mozaf farian D, Nye R, Levy WC. Statin therapy is associatedwith lower mortality among patients with severe heart failure[J].Am J Cardiol,2004,93(9):1124-1129.
[65]柯天秀,江芸,姜锋.阿托伐他汀对慢性充血性心力衰竭患者B型脑钠肽(BNP)的影响及疗效观察[J].海峡药学,2011,23(12)：116-117.
[66]Bauer sachs J, Galuppo P, Fraccarolb D, et al.Improvement of left ventricular remodeling and function by hydroxyme thylglut aryc cinenzyme a reductase Inhibit ion with heart failure after myocardial infarctionl[J].Circulation,2011,104(9):982-9851.
[67]宋芝萍,顾俊,陈跃光.阿托伐他汀对慢性心功能不全合并阵发性房颤预后的影响[J].国际心血管病杂志,2011,38(2)：126-128.
[68]Maggioni AP, Fabbri G, Lucci D, et al. Effect s of rosuvastatin on atrial fibrillat ionoccurrence:ancill ary results of the GISSI-H Ftrial[J].Eur Heart J,2009,30(19):2327-2336.
[69]Kulik A, Singh, JP, L evin R, et al. Association between stat inuse and the incidence of atrial fibrillation following hospitalization for cornaryartery disease[J].Am J Cardiol,2010,105(12):1655-1660.
[70]赵辉.阿托伐他汀对慢性心力衰竭患者脑钠肤、高敏c反应蛋白及心功能的影响[J].中国社区医师.医学专业,2011,13(29)：144-145.
[71]Horwieh TB, MaeLellan WR. Atorvastatin and stafins in the treatment of heart failure [J]. Expert Opin Pharmacother,2007,8(17):3061-3068.
[72]Ridker PM, RifaiN, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circrlation,1998,98:839-844.
[73]刘静,尤兆雄,王子超.阿托伐他汀对慢性心力衰竭患者炎症介质及心功能的影响[J].包头医学院学报,2008,24(5)：498.
[74]陶国华,金恒,吴红萍,等.阿托伐他汀对慢性心衰sCD40L、BNP水平的影响[J].中华全科医学,2011,9(4)：534-535.
[75]Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial [J].Lancet,2002,360:7-22.
[76]胡硕强,梁峰,李宁.阿托伐他汀对慢性心衰早期肾损害的短期疗效[J].中外医疗,2010,30(13)：23-24.
[77]Schmittdiel JA,Uratsu CS,Karter AJ,et al.Why dont diabetes patients achieve recommended risk factor targets?Poor adherence versus lack of treatment intensification[J].J Gen Intern Med,2008,23(5):588～594.
[78]Borghi C.Interactions between hypercholesterolemia and hypertension:implications for therapy[J].Curr Opin Nephrol Hypertens,2002,11:489-496.
[79]卢伟强.阿托伐他汀对心力衰竭患者干扰素γ和白细胞介素4的影响[J].吉林医学,2010,31(6)：742-743.
[80]Ferro D, Parro tto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinfl ammatory cytokines in patients with hypercholesterolemia[J]. J AM Coll Cardiol,2000,36(2):427.
[81]武智晓,黎明江.阿托伐他汀对心衰患者LVEF影响的Meta分析[J].海南医学,2012,23卷(1)：132-134.
[82]朱爱东,何云,张融,等.阿托伐他汀改善冠心病心力衰竭患者心功能的作用[J].重庆医学,2008,37(16)：1804-1805.
[83]付向东.阿托伐他汀对血脂水平正常心室重塑的影响[J].中国实用神经疾病杂志,2010,13(11)：25-27.
[84]刘厂辉,苏华.氟伐他汀对心衰患者血清TNF-A水平的影响[J].南华大学学报(医学版),2005,33：74-75.
[85]王辉华.阿托伐他汀钙对冠心病心力衰竭患者心功能的影响[J].中国医药指南,2012,10(35)：425-426.
[86]蒋方勇,韦金儒.血脂康对经皮冠状动脉介入治疗术后慢性稳定型心绞痛患者心肌标志物的影响[J].临床内科杂志,2008,25(9)：638
[87]姚水华.阿托伐他汀治疗非缺血性心脏病慢性心衰的临床效果[J].中国动脉硬化杂志,2011,19(4)：354-356.
[88]孔祥勇,胡世莲,沈干,等.阿托伐他汀治疗扩张型心肌病伴慢性充血性心力衰竭患者疗效的Meta分析[J].中国循证医学杂志,2012,12(10)：1223-1228.
[89]庄亮.阿托伐他汀治疗慢性充血性心力衰竭的临床研究[J].工企医刊,2009,22(5)：9-11.
[90]Young J B,Abraham W T,simth A L. et al.Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure:the MIRACLE ICD Trial.JAMA,2003, 289(20):2685-2694.
[91].Sodoht,Kangawak,Minaminon,etal. Anatriuretic peptide in porcine brain. [J].Nature,1988,322 (6159):78-81.
[92]徐丽,陈兰英.利钠肤的结构受体与生理作用.生物化学与生物物理进展,2002,29(5)：7801
[93]de Bold AJ, Bruneau BG, de Bold KML.Meehanieal and neuroendoerine regulation of the endocrine heart.Cardiovase Res,1996,31:7-18.
[94]夏思良,周建松,嵇平等.血浆脑钠肽前体N-末端水平在慢性收缩性心力衰竭患者中的诊断价值[J].临床内科杂志,2009,26(7)：19.
[95]邓少雄,林荣,郭南鸥.B型脑钠肽在心力衰竭中的诊断价值及其对近期预后的影响[J].实用临床医学2008,9(4).
[96]TamuraN,CgawaY,ChushoH,et al.Cardiac fibrosis in mice lacking brain natriuretic PePtide.Proe Natl Acad Sci USA,2000,97(8):4239-4244
[97]Yoshizumi M,Tsuji H.Nishimura H,et al.Natriuretic PePtides regulate the expression of tissue factor and PAI-1 in endothelial cells.ThrombHaemost,1999NoV,82(5):1497-1503
[98]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12)：1076-1095.
[99]赵丽,吴学思,韩智红,等.B型利钠肽检测对心力衰竭患者的临床评估[J].中华心血管病杂志,2004,32(1)：51-52.
[100]NT-proBNP临床应用中国专家建议书[J].中华心血管病杂志.2008,36(9)：830.
[101]汪芳,李一石,脑钠素在心力衰竭诊治中的应用进展[J].临床心血管病杂志,2004,20(10)：634-637.
[102]BAL,THIERRY S,BROCAS E, et al.3-type natriuretic peptide (BNP) and N-terminal-proBNP for heart failure diagnosis in shock or acute respiratory distress[J].Acute Anesthesiol Scand,2006,50 (3):340-347.
[103]季乃军,梅益斌,樊必夫等.心力衰竭患者血清脑钠素测定及其意义[J].放射免疫学杂志,2004,17(1)：15-16.
[104]杨跃进.应加强B型利钠肽在心力衰竭临床诊治中的应用研究[J].中国循环杂志2006,21(3)：161-162.
[105]李正章,程应樟,李菊香等.血浆脑钠肽结合超声心动图对心脏病患者心功能的评估[J].临床心血管病杂志,2008,24(12)：894-897.
[106]Thlevski Ⅱ,Mulder BJ, van2Veldhuisen DJ. Utilityof a BNP as a marker for RV dysfhaction in acute Pulmonary embolism. J Am Coll Cardiol,2002,39(12):2080-2084.
[107]Remme WJ,Swedberg K.Guidelines for the diagnosis and treatment of chronic Heart failure. Eur Heart J,2001,24(22):1527-1540.
[108]Harrison A,Morrison LK,Krishnaswamy P,et al.B-type natriuretic peptide Predicts future cardiac events in patients presenting to the emergeney Department with dyspnea. Ann Emerg Med,2002,39(2):131-138.
[109]白梅.脑钠肽在心力衰竭诊治中的研究进展.中国心血管病研究杂志,2005,3(11)：945-946.
[110]郑玉华.急性左心衰患者血浆脑钠肽水平变化与心功能远期预后的关系.现代实用医学,2005,17(7)：411-412.
[111]Tsutamoto T,Wada A,Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure:prognostic role of plasma brain natriuretic peptide concent ration in patients with chronic symptomatic left ventricular dysfunction. Circulation,1997,96(5):509-516.
[112]Schinkel AF,Vourvouri EC,Bax JJ,et al. Relation between left ventricular contractile reserve during low dose dobutamine echocardiography and plasma concentrations of natriuretic peptides. Heart,2004,90(3):293-296.
[113]Redfield MM,Rodeheffer RJ,Jacobsen SJ,et al. Plasma brain natriuretic peptide concentration:impact of age and gender. J Am Coll Cardiol,2002,40(5):976-982.
[114]Cheng V,Kazanagra R,Gareia A,et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure:A pilot study. J Am Coll Cardiol,2001,37(2):386-388.
[115]钟伟.冠心病充血性心力衰竭QT间期离散度分析(附123例临床报告)(摘要).中国循环杂志,1997,12(1)：11
[116]Jeffery D, Ho senpud, Barry H. Greenberg. Congest ive heart disease:pathoph siology, diagnosis, and comp rehensive approach to management.L i pp inco t tW illiam s & W ilk ins Inc [M]. USA,2000, Ch inese t ranslation,2004:85-90.
[117]Conrad CH,Brooks WW,Hays JA,et al.Myoeardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat[J].Circulation,1995,91:161-170.
[118]Chevalier B,Heudes D,Heymes G,et al.Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR[J].Circulation,1995,92:1947-1953.
[119]陈春安.急性心肌梗死QT离散度临床意义[J].第四军医大学学报,2002；23(4)：367-369
[120]朱强,栾怡华,王博.心梗患者QT离散度与心率变异性的关系[J].第四军医大学学报,2001；22(21)：1949-1952
[121]陆再英,钟南山主编.内科学[M]北京：人民卫生出版社,2008.170-173.
[122]Lars EM, Atsma DE, Kuijpers MMC, et al. The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes. Arch Biochem Biophys,1994, 313:58-63
[123]Kureishi Y, Luo Z, Shoijima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med,2000, 6:1004-1010
[124]Pliquett RU, Cornish KG, Zucker IH. Statin therapy restores sympathovagal balance in experimental heart failure.J Appl Physiol,2003,95:700-704
[125]Strehlow K, Wassmann S, Bohm M, et al. Angiotensin AT1 receptor over-expression in hypercholesterolemia.Ann Med,2000,32:386-389
[126].IsodaK.KamezawaY,TadaN,et al.Myoeardial hypertrophy in transgenic mice overexpressing human interleukin lalpha[J].CardFail2001,3(4),355-364.
[127]朱健,陈宜.细胞因子与高血压病患者左室构型的相关性研究[J].中华老年心脑血管病杂志,2005,7：166-168.
[128]Gaertner R, Lepailleur-Enouf D, Gonzalez W, et al. Pulmonary endothelium as a site of synthesis and storage of interleukin-6 in experimental congestive heart failure. Eur Heart,2003,5(4);435-442
[129]Mital S, Zhang X, Zhao G, et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs[J]. Am J Physiol Heart Circ Physiol,2000,279(6):2649-2657
[130]Balligand JL, Ungureahu-Longros D, Simmons W, et al. Induction of Nosynthase in rat cardiac microvascular endothelial cells by IL-1βND 1NF-r[J]. Am J Physiol,1995,268:H 1239-1303
[131]Li AC, Brown KK, Silvertre MJ, et al. Peroxisome prolifeator activated receptor-r ligand inhibit development of atherosclerosis in LDL receptor-deficient mice[J]. J Clin Invest,2000,106:523-553
[132].Barr CS, Nass A, FremanM, et al. QT dispersion and sudden unexpected death in chronic heart failure. Lancet,1994,343:327-329
[133]Aydinlar A, Senturk T,Ozdem " ir B,et al. Effect of percutaneous transluminal coronary angioplasty on QT dispersion and heart rate variability parameters[J]. Cardiovasc J Afr,2009,20(4):240-244
[134].许智韬,王伟,田清等.高血压患者左室肥厚与QT离散度分析.心脏杂志.2001；13(3)：239-240.
[135]].侯毅.高血压病患者QTc离散度与伴左室肥厚及恶性室性心律失常的关系.临床内科杂志.2002；19(2)：148-149.
[136]张琼,陈书艳.阿托伐他汀对大鼠心肌急性缺血细胞凋亡及Caspase-3基因表达影响[J]中华实用诊断与治疗杂志,2010,24(10)：965-967
[137]姚青海,崔长琮,吴尚勤,等.兔肥厚左心室跨壁复极离散度和室性心律失常的发生机制[J].中华心律失常学杂志,2006,10(2)：151-153.
[138]汤建武王丹童元焱慢性心力衰竭与QT离散度关系的探讨 当代医学2010年4月第16卷第12期总第203期
[139]纵静,唐其柱QT离散度对扩张型心肌病远期生存率的意义[J]临床荟萃杂志2009 11(5)21
[140]P-quett RU, Comi-KG, Peul-JD, et al. Simvastatin autoaomic neural control in experimental heart failure [J]. Circula-ioga。2003,107:2493 · 2498.
[141]赵莉芳,缪培智,陈齐虹,等阿托伐他汀对冠心病心力衰竭患者血浆钠尿肽水平及心功能的影响[J]内科理论与实践.2010,5(5)：418-421
[2].Cleland JGF.The heart failure epidemic:exactly how big is it.[J].Eur heart J,2001,22(8):623-626
[3].中华医学会心血管病学分会,中华心血管病杂志编辑部委员会.慢性收缩性心力衰竭治疗建议.[J].中华心血管病杂志,2002,30(6)：7
[4].杨光敏,唐国华,曹林生.心力衰竭发病机制研究进展[J].咸宁学院学报(医学版),2004,18(1)：11
[5]张子彬,Tsung O Cheng充血性心力衰竭(第2版).北京：科学技术文献出版社,1997,49-80.
[6].中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1)：723
[7]夏思良,周建松,嵇平等.血浆脑钠肽前体N-末端水平在慢性收缩性心力衰竭患者中的诊断价值[J].临床内科杂志,2009,26(7)：19.
[8].陆再英.钟南山.内科学[M].第七版,北京,人民卫生出版社,2008,1：174-175
[9]李延辉,那开宪.慢性心力衰竭的历史、现状和未来[J].中华临床杂志,2003,3(4)：53-59.据资料显示心衰患者占心血管病住院患者的20%,病死率却占40%以上[]。
[10]李玉珍,张晓华.慢性心力衰竭治疗的新理念[J].中国城乡企业卫生,2008,22(2)：37-38.
[11]杨红斌.慢性充血性心力衰竭药物治疗的研究进展[J].中国社区医师,2013,15(5)：10.
[12]Chamber DE, etal. MedCellCardioi,1985,17:145.
[13]高林荣.卡托普利联合芪苈强心胶囊治疗慢性肺心病难治性心衰疗效观察[J].中国社区医师,2013,15(5)：205.
[14]田蕊,李玲,苏真珍.β-受体阻滞剂与ACEI在心衰中的应用比较[J].中国民族民间医药,2009,17(16)：67.
[15]镇辉,柴祖德.常规抗心衰药加血管紧张素转换酶抑制剂(ACEI)治疗心力衰竭的疗效观察[J].中国血液流变学杂志,2005,15(4)：616.
[16]史爱民.抗心衰药物β1受体阻滞剂治疗心衰的疗效观察[J].山东生物医学工程,2001,20(3)：65.
[17]陆健.β1-受体阻滞剂治疗COPD并慢性心功能不全的临床观察[J].吉林医学,2011,32(21)：4316-4317.
[18]杜作义,聂如琼,王景峰.倍他乐克对慢性充血性心力衰竭患者心电生理特性的影响[J].吉林医学,广东医学,2001,22(8)：753-754.
[19]施仲伟.β受体治疗对慢性心力衰竭患者临床终点事件的影响[J].中华心血管病杂志,2001,29：504-505.
[20]韩昆峰.阿替洛尔治疗慢性充血性心力衰竭的疗效观察[J].实用心脑肺血管病杂志,2008,16(2)：120-121.
[21]李振魁,祝善俊,黄岚,等.美托洛尔长期治疗对慢性心力衰竭患者心肌重构和炎性细胞因子的影响[J].心脏杂志,2005,17(6)：517-518.
[22]杨丕俊,牛存龙,王书琨,等.美托洛尔治疗慢型克山病的效果观察[J].心脏杂志,2000,19(4)：298-299.
[23]黄登鹏,杨鸣,王少军,等.美托洛尔在治疗慢性肺心病心力衰竭中的应用[J].临床荟萃,2005,20(5)：251-252.
[24]席瑞霞,舒茂琴,张平.比索洛尔对慢性心力衰竭合并心房颤动患者的疗效分析席[J].重庆医学,2005,34(3)：387-388.
[25]梁晓坤.醛固酮受体拮抗剂临床应用研究进展[J].中国伤残医学,2012,20(7)：138-139.
[26]新春,李延辉.慢性心力衰竭治疗中醛固酮拮抗剂的应用[J].中国实用内科杂志,2005,25(7)：588-590.
[27]芦建华,那开宪.选择性醛固酮受体拮抗药依普利酮及其临床应用进展[J].首都医药,2005,12(150)：31-33.
[28]廖春分,丁洪成,廖勇敢.醛固酮受体拮抗剂对足细胞保护机制研究进展[J].实用医学杂志,2012,28(17)：2977-2978.
[29]Zhu C, Huang S, Yuan Y, et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage:A therapeutic target of PPARγ [J]. Am J Pathol,2011,178 (5):2020—2031.
[30]Agostoni P, Magini A, Andreini D, et al. Spironol actone improves lung diffusion in chronic heart failure. Eur H eart J,2005,26:159-164.
[31]杨新春,李延辉主编.现代心血管药物与临床.北京：人民军医出版社,2004.155-160.
[32]王辉华.阿托伐他汀钙对冠心病心力衰竭患者心功能的影响[J].中国医药指南,2012,10(35)：425-426.
[33]朱爱东,何云,张融,等.阿托伐他汀改善冠心病心力衰竭患者心功能的作用[J].重庆医学,2008,37(16)：1804-1805.
[34]Aseer E,Bertolami MC,Venturinelli ML,et al.Atorvaatatin reduces Proinflammatory markeB in hypercholesterolemic patients[J].Atherosclerosis,2004,177(1):161-166.
[35]袁晓利,王成全,高志刚.探讨阿托伐他汀钙在慢性心力衰竭治疗中的作用[J].中国伤残医学,2012,20(11)：91-92.
[36]刘冰.辛伐他汀对心衰大鼠高迁移率族蛋白1水平的影响[J].河北医学,2013,19(1)：53-56.
[37]武智晓,黎明江.阿托伐他汀对心衰患者LVEF影响Meta分析[J].海南医学,2012,23(1)：132-134.
[38]柯天秀,江芸,姜锋.阿托伐他汀对慢性充血性心力衰竭患者B型脑钠肽(BNP)的影响及疗效观察[J].海峡药学,2011,23(12)：116-117.
[39]白桂芝,樊蔚,袁江永,等.阿伐他汀对慢性心力衰竭患者LVEDD及血浆CRP和LDL-C的影响[J].贵阳医学院学报,2011,36(5)：519-520.
[40]邹操,陆文林,宋建平,等.辛伐他汀对心力衰竭家兔左室收缩功能及交感活性的影响[J].临床心血管病杂志,2011,27(9)：705-708.
[41]尚立中,林晓云,马绍椿,等.阿托伐他汀对扩张型心肌病患者心功能及心率变异性的影响.临床心血管病杂志,2004,20(3)：133-135.
[42]周翠珍,殷仁富,任雨笙,等.左旋卡尼汀对心力衰竭患者血清游离脂肪酸浓度的影响.心脏杂志,2004,16(3)：226-227.
[43]Charlap S, Lichstein E, William H, et al.Adrenergicblocking drug in the treatment of Congestive heart failure. Med Cli North Atn,2001,73(27):373.
[44]赵楚敏,王希柱,宋月霞.6分钟步行试验对氟伐他汀治疗慢性心衰的疗效评估[J].中国现代医药杂志,2009,11(12)：104-105.
[45]刘必卫.阿伐他汀治疗慢性心力衰竭39例临床观察[J].中国社区医师.医学专业,2011,13(35)：48
[46]贾志新,孟皓波,迎梅,等.阿司匹林、辛伐他汀和金纳多联合治疗高血压病的疗效分析[J].吉林大学学报(医学版),2011,37(5)：804.
[47]魏辉,李慧,陈礼学.阿托伐他汀对不伴有高胆固醇血症的慢性心衰患者的血管内皮功能的影响[J].心血管康复医学杂志,2010,19(2)：189-192.
[48]Cannon CP, Braunwald E, McCabe CH,etal.Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J]. N Engl J Med,2004,350(15):1495-1504.
[49]黄志军.阿托伐他汀对充血性心力衰竭患者炎症因子的影响[J].山东医药,2008,48(38)：76-77.
[50]Yam ada T, Node K, M ine T, et a.l Long-term effect of atorvastat in on neurohum oral activation and cardiac function in patients with chronic heart failure:a prospective randomized controlled study[J].Am H eart J,2007,153(6):1-8.
[51]赵献明,许春平,曾波,等.阿托伐他汀对充血性心衰患者肾功能的影响[J].中外医疗,2010,30：28-29.
[52]李文霞.阿托伐他汀对冠心病伴高脂血症患者血脂的影响[J].河北医药,2011,33(12)：1825-1826.
[53]袁伟,张尚杰.高胆固醇血症患者血管内皮功能变化及阿托伐他汀调脂治疗对其的影响[J].中西医结合心脑血管病杂志,2010,8：1182-1183.
[54]Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure[J]. JAMA,2006,296(17):2105-2111.
[55]余信强.阿托伐他汀对冠心病慢性心力衰竭患者的心功能和预后的影响[J].江汉大学学报(自然科学版),2009,37(3)：76-78
[56]RAINER U, PLIQUENT M D, KURTIS G, et al. Simvastatin normalizers autonomic neural control in experimental heart failure[J]. Circulation,2003,107(8):2493-2498.
[57]Pliquett RU, Cornish KG, Peuler JD, et al. Simvastatin normalizes autonomic neural control in experimental heart failure[J].Circulation,2003,107(19):2493-2498.
[58]陈晓,刘松.阿托伐他汀对急性心肌梗死合并心衰患者行PCI后血清H s-CRP和Copeptin的影响[J].山东医药,2010,50(5)：49-50.
[59]Kelly D, Squire IB, Khan SQ, et al. C-terminal provaso-press in(copeptin) is associated with left ventricu lardys-function, remodeling, and clin ical heart failu rein survivors of myocardial infarction[J]. J Card Fail,2008,14(9):739-745.
[60]孙俐俐,段丽敏,唐玉龙.阿托伐他汀对急性心肌梗死患者心功能影响研究[J].中国现代医生,2011,49(11)：27-28.
[61]UdeH JA, Ray JG. Primary and seconaary prevention of heart failure with stafins[J]. Expert Rev Cardiovasc Ther,2006,4 (6):917-926.
[62]欧荣华,文书银,邓小键.阿托伐他汀对扩张型心肌病心力衰竭的影响研究[J].医学信息,2011,8：3905-3907.
[63]邱宇安,陈火国,黄绍烈,等.阿托伐他汀对老年慢性心力衰竭患者心功能及高敏C反应蛋白水平的影响[J].临床荟萃,2010,25(17)：1490-1492.
[64]Mozaf farian D, Nye R, Levy WC. Statin therapy is associatedwith lower mortality among patients with severe heart failure[J].Am J Cardiol,2004,93(9):1124-1129.
[65]柯天秀,江芸,姜锋.阿托伐他汀对慢性充血性心力衰竭患者B型脑钠肽(BNP)的影响及疗效观察[J].海峡药学,2011,23(12)：116-117.
[66]Bauer sachs J, Galuppo P, Fraccarolb D, et al.Improvement of left ventricular remodeling and function by hydroxyme thylglut aryc cinenzyme a reductase Inhibit ion with heart failure after myocardial infarctionl[J].Circulation,2011,104(9):982-9851.
[67]宋芝萍,顾俊,陈跃光.阿托伐他汀对慢性心功能不全合并阵发性房颤预后的影响[J].国际心血管病杂志,2011,38(2)：126-128.
[68]Maggioni AP, Fabbri G, Lucci D, et al. Effect s of rosuvastatin on atrial fibrillat ionoccurrence:ancill ary results of the GISSI-H Ftrial[J].Eur Heart J,2009,30(19):2327-2336.
[69]Kulik A, Singh, JP, L evin R, et al. Association between stat inuse and the incidence of atrial fibrillation following hospitalization for cornaryartery disease[J].Am J Cardiol,2010,105(12):1655-1660.
[70]赵辉.阿托伐他汀对慢性心力衰竭患者脑钠肤、高敏c反应蛋白及心功能的影响[J].中国社区医师.医学专业,2011,13(29)：144-145.
[71]Horwieh TB, MaeLellan WR. Atorvastatin and stafins in the treatment of heart failure [J]. Expert Opin Pharmacother,2007,8(17):3061-3068.
[72]Ridker PM, RifaiN, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circrlation,1998,98:839-844.
[73]刘静,尤兆雄,王子超.阿托伐他汀对慢性心力衰竭患者炎症介质及心功能的影响[J].包头医学院学报,2008,24(5)：498.
[74]陶国华,金恒,吴红萍,等.阿托伐他汀对慢性心衰sCD40L、BNP水平的影响[J].中华全科医学,2011,9(4)：534-535.
[75]Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial [J].Lancet,2002,360:7-22.
[76]胡硕强,梁峰,李宁.阿托伐他汀对慢性心衰早期肾损害的短期疗效[J].中外医疗,2010,30(13)：23-24.
[77]Schmittdiel JA,Uratsu CS,Karter AJ,et al.Why dont diabetes patients achieve recommended risk factor targets?Poor adherence versus lack of treatment intensification[J].J Gen Intern Med,2008,23(5):588～594.
[78]Borghi C.Interactions between hypercholesterolemia and hypertension:implications for therapy[J].Curr Opin Nephrol Hypertens,2002,11:489-496.
[79]卢伟强.阿托伐他汀对心力衰竭患者干扰素γ和白细胞介素4的影响[J].吉林医学,2010,31(6)：742-743.
[80]Ferro D, Parro tto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinfl ammatory cytokines in patients with hypercholesterolemia[J]. J AM Coll Cardiol,2000,36(2):427.
[81]武智晓,黎明江.阿托伐他汀对心衰患者LVEF影响的Meta分析[J].海南医学,2012,23卷(1)：132-134.
[82]朱爱东,何云,张融,等.阿托伐他汀改善冠心病心力衰竭患者心功能的作用[J].重庆医学,2008,37(16)：1804-1805.
[83]付向东.阿托伐他汀对血脂水平正常心室重塑的影响[J].中国实用神经疾病杂志,2010,13(11)：25-27.
[84]刘厂辉,苏华.氟伐他汀对心衰患者血清TNF-A水平的影响[J].南华大学学报(医学版),2005,33：74-75.
[85]王辉华.阿托伐他汀钙对冠心病心力衰竭患者心功能的影响[J].中国医药指南,2012,10(35)：425-426.
[86]蒋方勇,韦金儒.血脂康对经皮冠状动脉介入治疗术后慢性稳定型心绞痛患者心肌标志物的影响[J].临床内科杂志,2008,25(9)：638
[87]姚水华.阿托伐他汀治疗非缺血性心脏病慢性心衰的临床效果[J].中国动脉硬化杂志,2011,19(4)：354-356.
[88]孔祥勇,胡世莲,沈干,等.阿托伐他汀治疗扩张型心肌病伴慢性充血性心力衰竭患者疗效的Meta分析[J].中国循证医学杂志,2012,12(10)：1223-1228.
[89]庄亮.阿托伐他汀治疗慢性充血性心力衰竭的临床研究[J].工企医刊,2009,22(5)：9-11.
[90]Young J B,Abraham W T,simth A L. et al.Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure:the MIRACLE ICD Trial.JAMA,2003, 289(20):2685-2694.
[91].Sodoht,Kangawak,Minaminon,etal. Anatriuretic peptide in porcine brain. [J].Nature,1988,322 (6159):78-81.
[92]徐丽,陈兰英.利钠肤的结构受体与生理作用.生物化学与生物物理进展,2002,29(5)：7801
[93]de Bold AJ, Bruneau BG, de Bold KML.Meehanieal and neuroendoerine regulation of the endocrine heart.Cardiovase Res,1996,31:7-18.
[94]夏思良,周建松,嵇平等.血浆脑钠肽前体N-末端水平在慢性收缩性心力衰竭患者中的诊断价值[J].临床内科杂志,2009,26(7)：19.
[95]邓少雄,林荣,郭南鸥.B型脑钠肽在心力衰竭中的诊断价值及其对近期预后的影响[J].实用临床医学2008,9(4).
[96]TamuraN,CgawaY,ChushoH,et al.Cardiac fibrosis in mice lacking brain natriuretic PePtide.Proe Natl Acad Sci USA,2000,97(8):4239-4244
[97]Yoshizumi M,Tsuji H.Nishimura H,et al.Natriuretic PePtides regulate the expression of tissue factor and PAI-1 in endothelial cells.ThrombHaemost,1999NoV,82(5):1497-1503
[98]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12)：1076-1095.
[99]赵丽,吴学思,韩智红,等.B型利钠肽检测对心力衰竭患者的临床评估[J].中华心血管病杂志,2004,32(1)：51-52.
[100]NT-proBNP临床应用中国专家建议书[J].中华心血管病杂志.2008,36(9)：830.
[101]汪芳,李一石,脑钠素在心力衰竭诊治中的应用进展[J].临床心血管病杂志,2004,20(10)：634-637.
[102]BAL,THIERRY S,BROCAS E, et al.3-type natriuretic peptide (BNP) and N-terminal-proBNP for heart failure diagnosis in shock or acute respiratory distress[J].Acute Anesthesiol Scand,2006,50 (3):340-347.
[103]季乃军,梅益斌,樊必夫等.心力衰竭患者血清脑钠素测定及其意义[J].放射免疫学杂志,2004,17(1)：15-16.
[104]杨跃进.应加强B型利钠肽在心力衰竭临床诊治中的应用研究[J].中国循环杂志2006,21(3)：161-162.
[105]李正章,程应樟,李菊香等.血浆脑钠肽结合超声心动图对心脏病患者心功能的评估[J].临床心血管病杂志,2008,24(12)：894-897.
[106]Thlevski Ⅱ,Mulder BJ, van2Veldhuisen DJ. Utilityof a BNP as a marker for RV dysfhaction in acute Pulmonary embolism. J Am Coll Cardiol,2002,39(12):2080-2084.
[107]Remme WJ,Swedberg K.Guidelines for the diagnosis and treatment of chronic Heart failure. Eur Heart J,2001,24(22):1527-1540.
[108]Harrison A,Morrison LK,Krishnaswamy P,et al.B-type natriuretic peptide Predicts future cardiac events in patients presenting to the emergeney Department with dyspnea. Ann Emerg Med,2002,39(2):131-138.
[109]白梅.脑钠肽在心力衰竭诊治中的研究进展.中国心血管病研究杂志,2005,3(11)：945-946.
[110]郑玉华.急性左心衰患者血浆脑钠肽水平变化与心功能远期预后的关系.现代实用医学,2005,17(7)：411-412.
[111]Tsutamoto T,Wada A,Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure:prognostic role of plasma brain natriuretic peptide concent ration in patients with chronic symptomatic left ventricular dysfunction. Circulation,1997,96(5):509-516.
[112]Schinkel AF,Vourvouri EC,Bax JJ,et al. Relation between left ventricular contractile reserve during low dose dobutamine echocardiography and plasma concentrations of natriuretic peptides. Heart,2004,90(3):293-296.
[113]Redfield MM,Rodeheffer RJ,Jacobsen SJ,et al. Plasma brain natriuretic peptide concentration:impact of age and gender. J Am Coll Cardiol,2002,40(5):976-982.
[114]Cheng V,Kazanagra R,Gareia A,et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure:A pilot study. J Am Coll Cardiol,2001,37(2):386-388.
[115]钟伟.冠心病充血性心力衰竭QT间期离散度分析(附123例临床报告)(摘要).中国循环杂志,1997,12(1)：11
[116]Jeffery D, Ho senpud, Barry H. Greenberg. Congest ive heart disease:pathoph siology, diagnosis, and comp rehensive approach to management.L i pp inco t tW illiam s & W ilk ins Inc [M]. USA,2000, Ch inese t ranslation,2004:85-90.
[117]Conrad CH,Brooks WW,Hays JA,et al.Myoeardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat[J].Circulation,1995,91:161-170.
[118]Chevalier B,Heudes D,Heymes G,et al.Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR[J].Circulation,1995,92:1947-1953.
[119]陈春安.急性心肌梗死QT离散度临床意义[J].第四军医大学学报,2002；23(4)：367-369
[120]朱强,栾怡华,王博.心梗患者QT离散度与心率变异性的关系[J].第四军医大学学报,2001；22(21)：1949-1952
[121]陆再英,钟南山主编.内科学[M]北京：人民卫生出版社,2008.170-173.
[122]Lars EM, Atsma DE, Kuijpers MMC, et al. The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes. Arch Biochem Biophys,1994, 313:58-63
[123]Kureishi Y, Luo Z, Shoijima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med,2000, 6:1004-1010
[124]Pliquett RU, Cornish KG, Zucker IH. Statin therapy restores sympathovagal balance in experimental heart failure.J Appl Physiol,2003,95:700-704
[125]Strehlow K, Wassmann S, Bohm M, et al. Angiotensin AT1 receptor over-expression in hypercholesterolemia.Ann Med,2000,32:386-389
[126].IsodaK.KamezawaY,TadaN,et al.Myoeardial hypertrophy in transgenic mice overexpressing human interleukin lalpha[J].CardFail2001,3(4),355-364.
[127]朱健,陈宜.细胞因子与高血压病患者左室构型的相关性研究[J].中华老年心脑血管病杂志,2005,7：166-168.
[128]Gaertner R, Lepailleur-Enouf D, Gonzalez W, et al. Pulmonary endothelium as a site of synthesis and storage of interleukin-6 in experimental congestive heart failure. Eur Heart,2003,5(4);435-442
[129]Mital S, Zhang X, Zhao G, et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs[J]. Am J Physiol Heart Circ Physiol,2000,279(6):2649-2657
[130]Balligand JL, Ungureahu-Longros D, Simmons W, et al. Induction of Nosynthase in rat cardiac microvascular endothelial cells by IL-1βND 1NF-r[J]. Am J Physiol,1995,268:H 1239-1303
[131]Li AC, Brown KK, Silvertre MJ, et al. Peroxisome prolifeator activated receptor-r ligand inhibit development of atherosclerosis in LDL receptor-deficient mice[J]. J Clin Invest,2000,106:523-553
[132].Barr CS, Nass A, FremanM, et al. QT dispersion and sudden unexpected death in chronic heart failure. Lancet,1994,343:327-329
[133]Aydinlar A, Senturk T,Ozdem " ir B,et al. Effect of percutaneous transluminal coronary angioplasty on QT dispersion and heart rate variability parameters[J]. Cardiovasc J Afr,2009,20(4):240-244
[134].许智韬,王伟,田清等.高血压患者左室肥厚与QT离散度分析.心脏杂志.2001；13(3)：239-240.
[135]].侯毅.高血压病患者QTc离散度与伴左室肥厚及恶性室性心律失常的关系.临床内科杂志.2002；19(2)：148-149.
[136]张琼,陈书艳.阿托伐他汀对大鼠心肌急性缺血细胞凋亡及Caspase-3基因表达影响[J]中华实用诊断与治疗杂志,2010,24(10)：965-967
[137]姚青海,崔长琮,吴尚勤,等.兔肥厚左心室跨壁复极离散度和室性心律失常的发生机制[J].中华心律失常学杂志,2006,10(2)：151-153.
[138]汤建武王丹童元焱慢性心力衰竭与QT离散度关系的探讨 当代医学2010年4月第16卷第12期总第203期
[139]纵静,唐其柱QT离散度对扩张型心肌病远期生存率的意义[J]临床荟萃杂志2009 11(5)21
[140]P-quett RU, Comi-KG, Peul-JD, et al. Simvastatin autoaomic neural control in experimental heart failure [J]. Circula-ioga。2003,107:2493 · 2498.
[141]赵莉芳,缪培智,陈齐虹,等阿托伐他汀对冠心病心力衰竭患者血浆钠尿肽水平及心功能的影响[J]内科理论与实践.2010,5(5)：418-421